Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silver. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28656336 | 0.95 | RAPGEF4 (0.54) | RAPGEF4CA1CA2MMP1MMP2 | |
| Lithium Ion SCHEMBL28656990 | 0.95 | RAPGEF4 (0.54) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL1499866 | 0.95 | RAPGEF4 (0.54) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL9165326 | 0.95 | RAPGEF4 (0.54) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL6274955 | 0.95 | RAPGEF4 (0.54) | RAPGEF4CA1CA2MMP1MMP2 | |
| Potassium Ion SCHEMBL28668574 | 0.95 | RAPGEF4 (0.54) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL11837095 | 0.89 | RAPGEF4 (0.48) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL646619 | 0.87 | RAPGEF4 (0.47) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL4541179 | 0.79 | RAPGEF4 (0.44) | RAPGEF4CA1CA2MMP1MMP2 | |
| SCHEMBL1694111 | 0.79 | RAPGEF4 (0.41) | RAPGEF4CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663398-B1 | Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE | CALIFORNIA INST OF TECHN (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9597674-B2 | Z-selective olefin metathesis catalysts and their synthetic procedure | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-03-21 | — | — | US | disclosed |
| CN-103402628-B | Z-selective olefin metathesis catalyst and synthesis step thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-23 | — | — | CN | disclosed |
| US-9057929-B2 | Quinolinium single crystals for use in nonlinear optics | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-06-16 | — | — | US | disclosed |
| US-20140204457-A1 | QUINOLINIUM SINGLE CRYSTALS FOR USE IN NONLINEAR OPTICS | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2014-07-24 | — | — | US | disclosed |
| US-20140106960-A1 | Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-04-17 | — | — | US | disclosed |
| EP-2663398-A2 | Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE | California Institute of Technology (US) | 2013-11-20 | — | — | EP | disclosed |
| CN-103402628-A | Z-selective olefin metathesis catalysts and their synthetic procedure | CALIFORNIA INST OF TECHN | 2013-11-20 | — | — | CN | disclosed |
| WO-2012097379-A2 | Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2012-07-19 | — | — | WO | disclosed |
| US-5424378-A | Catalyzing in the presence of a mixture comprising an alkyl-sulfonate cyclopentadienyl titanium or zirconium compound and an aluminoxane | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| US-5412128-A | Catalyst for olefin polymerization, process for the polymerization of olefin, and transition metal compound employable for the catalyst | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5409874-A | Containing transition metal compound having cyclopentadienyl skeleton and sulfonate group, aluminoxane or benzene insoluble organoaluminum compound | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| EP-0519746-A1 | Catalyst for olefin polymerization, process for the polymerization of olefin, and transition metal compound employable for the catalyst | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-4489091-A | ESTERASE AND ANTIBODY INHIBITORS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1984-12-18 | — | — | US | disclosed |
| US-4411911-A | Method of treating hyperlipidemia and inflammation with sulfonate derivatives | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140106960-A1 | Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE | OPRM1, C1R, NPY2R | RAPGEF4 3991/4885CA1 537/4885CA2 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.